Abstract: Objective:To observe the efficacy of cytokine-induced killer (CIK) cells on patients with advanced lung cancer. Methods:A total of 90patients with advanced lung cancer were identified from January 2011to December 2013. CIK therapy was given to 41pa-tients in the observation group, whereas the other 49patients in the control group received the best support treatments without che-motherapy or radiotherapy within one month of inclusion. Following up was conducted for the patients in the two groups, and KPS scores, median survival, and adverse reactions compared. Results:The KPS score in the observation group was higher than that of the control group after treatment (P=0. 034 ). The median survival period of the observation group was eight months, which was one month longer than that of the control group ( P=0. 044 ). Major adverse reactions included fever, joint pain, and insomnia, which were recorded 51. 22%,36. 58%, and 29. 27% of occurrence, respectively.Conclusion: CIK cell therapy improved the quality of life and pro-longed the survival of advanced lung cancer patients with tolerable adverse reactions.